Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

類似資料

• EGFR activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity
  著者:: Pfäffle, Heike N., 等
  出版事項: (2013)
• Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers
  著者:: Khandekar, Melin J., 等
  出版事項: (2018)
• Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?
  著者:: Piotrowska, Zofia, 等
  出版事項: (2015)
• Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period
  著者:: McClatchy, David M., 等
  出版事項: (2020)
• The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies
  著者:: Niederst, Matthew J., 等
  出版事項: (2015)